Early Aggressive Treatment Approaches for Multiple Sclerosis

Real‐World Effectiveness of Initial Disease‐Modifying Therapies in Pediatric Multiple Sclerosis

(2020) Kristen M. Krysko et al.   ANNALS OF NEUROLOGY

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study

(2020) Anna He et al.   LANCET NEUROLOGY

Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort

(2020) Annette Langer-Gould et al.   NEUROLOGY

Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World Study

(2020) Luca Prosperini et al.   Neurotherapeutics

Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder

(2020) Andrea Ines Ciplea et al.   Neurology-Neuroimmunology & Neuroinflammation

An Italian programme for COVID-19 infection in multiple sclerosis

(2020) Maria Pia Sormani   LANCET NEUROLOGY

Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study

(2020) Helmut Butzkueven et al.   BMJ Open

Cladribine vs other drugs in MS

(2020) Alessio Signori et al.   Neurology-Neuroimmunology & Neuroinflammation

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

(2019) J. William L. Brown et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis

(2019) Katharine Harding et al.   JAMA Neurology

Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a Review of Current Literature and Future Directions for Transplant Haematologists and Oncologists

(2019) Joyutpal Das et al.   Current Hematologic Malignancy Reports

Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing–remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches

(2019) Andrea Berardi et al.   CURRENT MEDICAL RESEARCH AND OPINION

Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation

(2019) Jeffrey A. Cohen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis

(2019) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies

(2019) Lori Mayer et al.   Multiple Sclerosis and Related Disorders

Risk of relapses during pregnancy among multiple sclerosis patients

(2019) Raed Alroughani et al.   Multiple Sclerosis and Related Disorders

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

(2019) Gustavo Luna et al.   JAMA Neurology

Minimal breast milk transfer of rituximab, a monoclonal antibody used in neurological conditions

(2019) Kristen M. Krysko et al.   Neurology-Neuroimmunology & Neuroinflammation

Association Between Breastfeeding and Postpartum Multiple Sclerosis Relapses

(2019) Kristen M. Krysko et al.   JAMA Neurology

Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data

(2018) Jing Chen et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study

(2018) Gavin Giovannoni et al.   Multiple Sclerosis Journal

Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis

(2018) Mathias Granqvist et al.   JAMA Neurology

Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study

(2018) Gavin Giovannoni et al.   Multiple Sclerosis Journal

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis

(2018) Tanuja Chitnis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US

(2018) Kristen M. Krysko et al.   NEUROLOGY

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

(2017) Tomas Kalincik et al.   LANCET NEUROLOGY

Disease-modifying therapies modulate retinal atrophy in multiple sclerosis

(2017) Julia Button et al.   NEUROLOGY

Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis

(2017) Jeffrey M. Gelfand et al.   Neurotherapeutics

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis

(2017) Paolo A. Muraro et al.   JAMA Neurology

Predictors of long-term disability accrual in relapse-onset multiple sclerosis

(2016) Vilija G. Jokubaitis et al.   ANNALS OF NEUROLOGY

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

(2016) Peter Alping et al.   ANNALS OF NEUROLOGY

Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis

(2016) Luca Prosperini et al.   JOURNAL OF NEUROLOGY

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

(2016) Nathaniel Lizak et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis

(2016) Hyunwoo Lee et al.   Multiple Sclerosis Journal

Hispanic Americans and African Americans with multiple sclerosis have more severe disease course than Caucasian Americans

(2016) Rachel E Ventura et al.   Multiple Sclerosis Journal

Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis

(2016) Hyunwoo Lee et al.   Multiple Sclerosis Journal

Hispanic Americans and African Americans with multiple sclerosis have more severe disease course than Caucasian Americans

(2016) Rachel E Ventura et al.   Multiple Sclerosis Journal

Brain health: time matters in multiple sclerosis

(2016) Gavin Giovannoni et al.   Multiple Sclerosis and Related Disorders

Is Time to Reach EDSS 6.0 Faster in Patients with Late-Onset versus Young-Onset Multiple Sclerosis?

(2016) Raed Alroughani et al.   PLoS One

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

(2015) Tomas Kalincik et al.   ANNALS OF NEUROLOGY

Natalizumab in the pediatric MS population: results of the Italian registry

(2015) Angelo Ghezzi et al.   BMC Neurology

Defining high, medium and low impact prognostic factors for developing multiple sclerosis

(2015) Mar Tintore et al.   BRAIN

Rituximab in paediatric onset multiple sclerosis: a case series

(2015) Jonatan Salzer et al.   JOURNAL OF NEUROLOGY

Multiple sclerosis and pregnancy in the 'treatment era'

(2015) Sandra Vukusic et al.   Nature Reviews Neurology

JC virus antibody status in a pediatric multiple sclerosis cohort: Prevalence, conversion rate and influence on disease severity

(2014) Peter Huppke et al.   Multiple Sclerosis Journal

Monoclonal antibodies in treatment of multiple sclerosis

(2013) P. S. Rommer et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Predictive value of 1 month retinal nerve fiber layer thinning for deficits at 6 months after acute optic neuritis

(2013) Mark J Kupersmith et al.   Multiple Sclerosis Journal

Predictors and dynamics of postpartum relapses in women with multiple sclerosis

(2013) Stella E Hughes et al.   Multiple Sclerosis Journal

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

‘Clinically definite benign multiple sclerosis’, an unwarranted conceptual hodgepodge: evidence from a 30-year observational study

(2012) E Leray et al.   Multiple Sclerosis Journal

Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis

(2011) David B. Clifford   ARCHIVES OF NEUROLOGY

Management of Pediatric Central Nervous System Demyelinating Disorders: Consensus of United States Neurologists

(2011) Amy T. Waldman et al.   JOURNAL OF CHILD NEUROLOGY

The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability

(2010) Antonio Scalfari et al.   BRAIN

Poor recovery after the first two attacks of multiple sclerosis is associated with poor outcome five years later

(2010) Thomas F. Scott et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Early cognitive impairment in multiple sclerosis predicts disability outcome several years later

(2010) Mathilde Deloire et al.   Multiple Sclerosis Journal

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

(2010) Gavin Giovannoni et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

Increased Relapse Rate in Pediatric-Onset Compared With Adult-Onset Multiple Sclerosis

(2009) Mark P. Gorman et al.   ARCHIVES OF NEUROLOGY

Demyelinating events in early multiple sclerosis have inherent severity and recovery

(2009) E. M. Mowry et al.   NEUROLOGY

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE